Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Arbutus Biopharma Corporation’s 10-K, filed March 23, 2026.
- Filed
- Mar 23, 2026, 7:30 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001447028-26-000017
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 |
|---|---|---|
| Purchase of investments in marketable securities | (140,061) | (141,509) |
| Disposition of investments in marketable securities | 155,277 | 164,639 |
| Proceeds from sale of property and equipment | 364 | — |
| Acquisition of property and equipment | — | (182) |
| Net cash provided by investing activities | 15,580 | 22,948 |
| FINANCING ACTIVITIES | ||
| Issuance of common shares pursuant to the Open Market Sale Agreement | — | 44,123 |
| Issuance of common shares pursuant to exercise of stock options | 5,540 | 7,477 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Arbutus Biopharma Corporation's capex?
- Arbutus Biopharma Corporation (ABUS) reported capex of $0 in Q4 2025.
- How has Arbutus Biopharma Corporation's capex changed year-over-year?
- Arbutus Biopharma Corporation's capex decreased by 100.0% year-over-year, from $86K to $0.
- What is the long-term trend for Arbutus Biopharma Corporation's capex?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's capex has grown at a -100.0% compound annual growth rate (CAGR), from $809K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Arbutus Biopharma Corporation's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude